AU2009224004A1 - Tricyclic derivatives as inhibitors of poly(ADP-ribose)polymerase (PARP) - Google Patents

Tricyclic derivatives as inhibitors of poly(ADP-ribose)polymerase (PARP) Download PDF

Info

Publication number
AU2009224004A1
AU2009224004A1 AU2009224004A AU2009224004A AU2009224004A1 AU 2009224004 A1 AU2009224004 A1 AU 2009224004A1 AU 2009224004 A AU2009224004 A AU 2009224004A AU 2009224004 A AU2009224004 A AU 2009224004A AU 2009224004 A1 AU2009224004 A1 AU 2009224004A1
Authority
AU
Australia
Prior art keywords
alkyl
compound
compounds
independently selected
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009224004A
Other languages
English (en)
Inventor
Raffaele Ingenito
Philip Jones
Laura Llauger Bufi
Jesus Maria Ontoria Ontoria
Rita Scarpelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Original Assignee
St Di Ricerche Di Biologia Molecolare P Angeletti SpA
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Di Ricerche Di Biologia Molecolare P Angeletti SpA, Istituto di Ricerche di Biologia Molecolare P Angeletti SpA filed Critical St Di Ricerche Di Biologia Molecolare P Angeletti SpA
Publication of AU2009224004A1 publication Critical patent/AU2009224004A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2009224004A 2008-03-14 2009-03-13 Tricyclic derivatives as inhibitors of poly(ADP-ribose)polymerase (PARP) Abandoned AU2009224004A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0804755.7A GB0804755D0 (en) 2008-03-14 2008-03-14 Therapeutic compounds
GB0804755.7 2008-03-14
PCT/GB2009/000661 WO2009112832A1 (en) 2008-03-14 2009-03-13 Tricyclic derivatives as inhibitors of poly(adp-ribose)polymerase (parp)

Publications (1)

Publication Number Publication Date
AU2009224004A1 true AU2009224004A1 (en) 2009-09-17

Family

ID=39328122

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009224004A Abandoned AU2009224004A1 (en) 2008-03-14 2009-03-13 Tricyclic derivatives as inhibitors of poly(ADP-ribose)polymerase (PARP)

Country Status (7)

Country Link
US (1) US8362030B2 (enExample)
EP (1) EP2265611A1 (enExample)
JP (1) JP2011513475A (enExample)
AU (1) AU2009224004A1 (enExample)
CA (1) CA2716918C (enExample)
GB (1) GB0804755D0 (enExample)
WO (1) WO2009112832A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9216998B2 (en) * 2012-02-15 2015-12-22 Janssen Pharmaceutica Nv Tricyclic indole derivatives useful endothelial lipase inhibitors
US9512486B2 (en) * 2012-08-06 2016-12-06 The Institute Of Cancer Research: Royal Cancer Hospital Materials, methods, and systems for treating cancer
KR101670126B1 (ko) 2013-09-13 2016-10-27 일동제약(주) 신규 프탈라지논 유도체 및 그 제조방법
CN103936735B (zh) * 2014-04-04 2015-11-11 沈阳工业大学 氮杂苯并薁衍生物及其制备方法和用途
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
EP3265560B1 (en) 2015-03-02 2021-12-08 Sinai Health System Homologous recombination factors
WO2018138050A1 (de) 2017-01-26 2018-08-02 Bayer Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
JP6737967B1 (ja) * 2017-07-18 2020-08-12 ロンザ リミテッドＬｏｎｚａ Ｌｉｍｉｔｅｄ ５−フルオロ−２−メチル−３−ニトロ安息香酸およびそのメチルエステルを製造する方法
WO2019016110A1 (en) * 2017-07-18 2019-01-24 Lonza Ltd PROCESS FOR THE PREPARATION OF 5-FLUORO-2-METHYL-3-NITROBENZOIC ACID AND METHYL ESTER
CA3128435A1 (en) * 2019-02-02 2020-08-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Indolo heptamyl oxime analogue as parp inhibitor
WO2021214502A1 (en) 2020-04-21 2021-10-28 Idience Co., Ltd. Process for preparing a phthalazinone derivative and intermediates thereof
IL297464A (en) 2020-04-21 2022-12-01 Idience Co Ltd Crystalline forms of phthalazinone compound
US12059419B2 (en) 2020-10-16 2024-08-13 Idience Co., Ltd. Pharmaceutical composition comprising phthalazinone derivatives
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
CN117105958B (zh) * 2022-05-24 2025-08-29 科岭源生物科技(深圳)有限公司 一种制备5-ht3受体调节剂的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719147A (en) 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
EP0771319A1 (en) 1994-07-15 1997-05-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
US5958942A (en) * 1994-07-15 1999-09-28 Takeda Chemical Industries, Ltd. Tricyclic nitrogen ring compounds, their production and use
CA2214393A1 (en) 1996-09-02 1998-03-02 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
AU5340298A (en) 1996-12-27 1998-07-31 Takeda Chemical Industries Ltd. Stabilized tricyclic compound
WO1999059975A1 (en) * 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
PL210415B1 (pl) 1999-01-11 2012-01-31 Agouron Pharma Pochodne indolu, środek farmaceutyczny i zastosowanie pochodnych indolu
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
WO2001023390A2 (de) * 1999-09-28 2001-04-05 Basf Aktiengesellschaft Azepinoindol-derivate, deren herstellung und anwendung
ES2290115T3 (es) 2000-02-01 2008-02-16 ABBOTT GMBH & CO. KG Compuestos heterociclicos y su aplicacion como inhibidores de parp.
FR2816942B1 (fr) 2000-11-23 2003-05-09 Sanofi Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
ATE478664T1 (de) * 2000-12-01 2010-09-15 Eisai Inc Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
ES2286328T3 (es) * 2001-12-27 2007-12-01 Ortho-Mcneil Pharmaceutical, Inc. Aroilpirrolheteroaril y metanoles utiles para tratar transtornos del sistema nervioso central.
EP1611137A1 (en) 2003-03-31 2006-01-04 Pfizer Inc. Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
ATE454893T1 (de) * 2003-07-25 2010-01-15 Cancer Rec Tech Ltd Tricyclische parp-hemmer
AU2005216978A1 (en) 2004-02-26 2005-09-09 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
AU2005276229A1 (en) 2004-08-26 2006-03-02 Kudos Pharmaceuticals Limited 4-heteroarylmethyl substituted phthalazinone derivatives
JP4611441B2 (ja) 2006-04-03 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール及びベンゾトリアゾール誘導体
EP2032140A1 (en) * 2006-05-31 2009-03-11 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase(parp)
GB0612971D0 (en) * 2006-06-30 2006-08-09 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0615809D0 (en) * 2006-08-09 2006-09-20 Istituto Di Ricerche D Biolog Therapeutic compounds

Also Published As

Publication number Publication date
WO2009112832A1 (en) 2009-09-17
JP2011513475A (ja) 2011-04-28
CA2716918A1 (en) 2009-09-17
CA2716918C (en) 2013-07-02
US20110053911A1 (en) 2011-03-03
GB0804755D0 (en) 2008-04-16
EP2265611A1 (en) 2010-12-29
US8362030B2 (en) 2013-01-29

Similar Documents

Publication Publication Date Title
US8362030B2 (en) Tricyclic derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP)
CA2653529C (en) Pyridinone and pyridazinone derivatives as inhibitors of poly(adp-ribose)polymerase (parp)
EP2007733B1 (en) Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors
US7834015B2 (en) Pyrrolo[1,2-a] pyrazin-1(2H)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose)polymerase (PARP)
US8354413B2 (en) Quinolin-4-one and 4-oxodihydrocinnoline derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP)
US20100152180A1 (en) 4-oxo-4,5-dihydropyrrolo[1,2-A)quinoxaline derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP)
WO2008001134A1 (en) 1,2,3,8,9,9a-hexahydro-7h-benzo(de)-1,7-naphthyridin-7-one derivatives as inhibitors of poly(adp-ribose) polymerase (parp)
US20100173895A1 (en) Imidazolopyrimidines and imidazolotriazine derivatives as inhibitors of poly(adp-ribose)polymerase(parp)
WO2012006958A1 (en) Amids substituted indazole derivativees as ploy(adp-ribose)polymerase inhibitors
WO2008041037A1 (en) Fused indoles and indazoles as inhibitors of poly(adp-ribose)polymerase (parp)

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application